# US 4,391,802 A · Method of treating leukemia or leukemoid diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,391,802 A
- Document ID: US4391802A
- Status: Granted
- Kind: A
- Application number: 06/356,385
- Filed: 1982-03-09
- Granted: 1983-07-05
- Earliest claimed: 1981-03-13
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Tatsuo Suda; Yoshihei Hirasawa; Sachio Takahashi; Etsuko Abe; Kunio Konno; Tadao Aoki
- Web page: https://patentgrep.com/patent/US4391802A

## CPC

- A61K 31/59: Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of leukemia or leukemoid disease treatment by administration of a vitamin D derivative with a hydroxyl group at 1.alpha.-position is disclosed. It is believed that the vitamin D derivative with a hydroxyl group at 1.alpha.-position is capable of treating cancer through redifferentiation of cancer cells and that this capability is inherent in vitamin D derivatives with a hydroxyl group at 1.alpha.-position.

## Claims

### Claim 1

A method for the treatment of leukemia or leukemoid diseases, comprising administering to a patient having such a disease an effective amount of a vitamin D derivative with a hydroxyl group at the 1.alpha.-position.

### Claim 2 (depends on 1)

A method according to claim 1 wherein said derivative is administered in a soft capsule.

### Claim 3 (depends on 1)

A method according to claim 1 wherein said derivative is administered in a daily dose of 0.5 to 5 .mu.g.

### Claim 4 (depends on 1)

A method according to claim 1 for the treatment of leukemia, wherein the patient has leukemia.

### Claim 5 (depends on 4)

A method according to claim 4 wherein the leukemia is a myelogenous leukemia.

### Claim 6 (depends on 1)

A method according to claim 1 wherein said derivative is 1.alpha.-hydroxyvitamin D.sub.3.

### Claim 7 (depends on 1)

A method according to claim 1 wherein said derivative is 1.alpha.,25-dihydroxyvitamin D.sub.3.

### Claim 8 (depends on 1)

A method in accordance with claim 1, wherein said derivative is 1.alpha.-hydroxyvitamin D.sub.3, 1.alpha.,25-dihydroxyvitamin D.sub.3 or a mixture thereof.